Skip to main
LIVN
LIVN logo

Livanova (LIVN) Stock Forecast & Price Target

Livanova (LIVN) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 31%
Hold 31%
Sell 0%
Strong Sell 0%

Bulls say

LivaNova has demonstrated an operating margin improvement of 180 basis points year-over-year, driven by gross margin expansion and strategic SG&A leverage, indicating strong operational efficiency. The company is projected to achieve mid-single-digit revenue growth of 6.7% for 2024, with expectations for cardiopulmonary organic growth of 7.0-8.0% in 2025, bolstered by the launch of the Essenz HLM and increased market share in oxygenators. Additionally, LivaNova's capacity for oxygenator production has improved by 10% in 2024, with anticipated further enhancements of 10-15% in 2025, positioning the company well for future revenue growth as elective procedures rebound post-pandemic.

Bears say

LivaNova's recent financial performance indicates a concerning trend, with neuromodulation sales growing only 1.0% to $137.6 million, a significant decline from the 8.8% growth observed in the previous quarter, and challenges in its OUS epilepsy business due to personnel changes. While cardiopulmonary sales experienced an 11.2% increase, this was also a decrease from the previous quarter's 15.4% growth, suggesting potential headwinds in sustaining momentum across key segments. Furthermore, the company's guidance indicates a slowdown in organic revenue growth to 7% for 4Q24, down from 12% in 3Q24, alongside expectations of operating margin contraction, contributing to a bearish outlook on its future performance.

Livanova (LIVN) has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 31% recommend Buy, 31% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Livanova (LIVN) Forecast

Analysts have given Livanova (LIVN) a Buy based on their latest research and market trends.

According to 13 analysts, Livanova (LIVN) has a Buy consensus rating as of Jun 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Livanova (LIVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.